Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.

Cancer treatment reviews - 1 Apr 2016

Sunakawa Y, Bekaii-Saab T, Stintzing S

Abstract excerpt

Colorectal cancer is one of the most frequent solid tumors in the western world, with low survival rates in patients with metastatic disease. Doublet chemotherapy regimens such as FOLFOX or FOLFIRI are the mainstay of standard first-line chemotherapy in the metastatic setting. The conventional treatment as a first-line approach is continuous application until progression or intolerable toxicities. However, only...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Fluorouracil
Share to Leucovorin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Maintenance Chemotherapy

Share to Neoplasm Metastasis

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Pharmacokinetics

Source

Identifiers

PMID: 27002945
DOI: 10.1016/j.ctrv.2016.03.007

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.PMID 27002945Read ↗

Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAFV600E mutation status.Semantic proximity Read ↗

Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left-sided RAS/BRAF wild-type metastatic colorectal cancer: the IMPROVE-2 trialSemantic proximity Read ↗

Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.Semantic proximity Read ↗

Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.Semantic proximity Read ↗

Does capecitabine maintenance therapy versus active monitoring confer a survival benefit after first-line treatment of metastatic colorectal cancer? A meta-analysis of randomized controlled trialsSemantic proximity Read ↗

A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.Semantic proximity Read ↗

Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC.Semantic proximity Read ↗

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.Semantic proximity Read ↗

The Survival Impact of Fluoropyrimidine Metronomic Maintenance Therapy Following Adjuvant Oxaliplatin-based Chemotherapy in Patients with Stage III Colorectal Cancer after Radical Resection: Functional Roles of EGFR as a Potential PredictorSemantic proximity Read ↗

Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.Semantic proximity Read ↗

Predictive Values of EGFR expression for the Fluoropyrimidine Metronomic Maintenance Therapy in Patients with Stage III Colorectal Cancer after Radical Resection and Adjuvant Oxaliplatin-Based ChemotherapySemantic proximity Read ↗

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.